SLC16A10

Across TCGA pan-cancer cohorts, SLC16A10 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC16A10 data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC16A10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC16A10 expression acts as an unfavorable survival marker.

PDAC and LSCC are the cancer types where SLC16A10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.443	0.937	.047	3	view →
LSCC	DFS	Quartile	All	0.923	1.000	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SLC16A10–PDAC (OS)

Open the PDAC breakdown →